Clin Lung Cancer 2022 Jun 3. Epub 2022 Jun 3.
Department of Medicine, Stanford University School of Medicine, Stanford, CA; Division of Oncology, Stanford University School of Medicine, Stanford, CA; Stanford Cancer Institute, Stanford, CA. Electronic address:
Introduction: About 3%-5% of mNSCLC have ERBB2 (HER2) alterations, but currently, there are no FDA-approved targeted therapies for this indication. We compared treatment response between trastuzumab-based and non-targeted regimens in ERBB2-mutant mNSCLC.
Methods: This retrospective, single-institution study included patients with mNSCLC with ERBB2 alterations identified by next-generation sequencing. Read More